The emerging crisis of drug-resistant tuberculosis in South Africa: Lessons from New York City

Clinical Infectious Diseases

Volumn 46, Issue 11, 2008, Pages 1729-1732

  Murphy, Richard A ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MÉDECINS SANS FRONTIÈRES   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ISONIAZID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN;

DISEASE TRANSMISSION; HOSPITAL INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; PATIENT CARE; PRIORITY JOURNAL; REVIEW; SOUTH AFRICA; TUBERCULOSIS; UNITED STATES;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COMMUNICABLE DISEASES, EMERGING; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HIV INFECTIONS; HUMANS; SOUTH AFRICA; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 43949087247     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/587903     Document Type: Review

References (15)

1. Munsiff SS, Li J, Cook SV, et al. Trends in drug-resistant Mycobacterium tuberculosis in New York City, 1991-2003. Clin Infect Dis 2006; 42:1702-10.
2. Frieden TR, Sterling T, Pablos-Mendez A, Kilburn JO, Cauthen GM, Dooley SW. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 1993; 328:521-6.
3. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368:1575-80.
4. Turett GS, Telzak EE, Torian LV, et al. Improved outcomes for patients with multidrug-resistant tuberculosis. Clin Infect Dis 1995; 21:1238-44.
5. Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003; 348:119-28.
6. Sterling TR. Drug-resistant tuberculosis in New York City: lessons to remember. Clin Infect Dis 2006; 42:1711-2.
7. Brudney K, Dobkin J. Resurgent tuberculosis in New York City: human immunodeficiency virus, homelessness, and the decline of tuberculosis control programs. Am Rev Respir Dis 1991; 144:745-9.
8. World Health Organization (WHO). Global tuberculosis control: surveillance, planning, financing. WHO report 2007. Geneva: WHO, 2007.
9. Frieden TR, Fujiwara PI, Washko RM, Hamburg MA. Tuberculosis in New York City - turning the tide. N Engl J Med 1995; 333:229-33.
10. Schluger N, Ciotoli C, Cohen D, Johnson H, Rom WN. Comprehensive tuberculosis control for patients at high risk for noncompliance. Am J Respir Crit Care Med 1995; 151:1486-90.
11. el-Sadr W, Medard F, Berthaud V. Directly observed therapy for tuberculosis: the Harlem Hospital experience, 1993. Am J Public Health 1996; 86:1146-9.
12. Edlin BR, Tokars JI, Grieco MH, et al. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med 1992; 326:1514-21.
13. Small PM, Shafer RW, Hopewell PC, et al. Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med 1993; 328:1137-44.
14. Fischl MA, Uttamchandani RB, Daikos GL, et al. An outbreak of tuberculosis caused by multiple-drug-resistant tubercle bacilli among patients with HIV infection. Ann Intern Med 1992; 117:177-83.
15. Bock N, Jensen P, Walton W, et al. Tuberculosis infection control in the era of expanding HIV care and treatment: addendum to WHO guidelines for the prevention of tuberculosis in health care facilities in resource-limited settings, 1999. Available at: http://www.who.int/tb/publications/2006/ tbhiv_infectioncontrol_addendum.pdf. Accessed 16 April 2008.